Ignite Creation Date:
2025-12-24 @ 2:28 PM
Ignite Modification Date:
2025-12-28 @ 6:48 AM
Study NCT ID:
NCT03913559
Status:
RECRUITING
Last Update Posted:
2025-07-03
First Post:
2019-04-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
Sponsor:
St. Jude Children's Research Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-05-14
Start Date Type:
ACTUAL
Primary Completion Date:
2029-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-12
Completion Date Type:
ESTIMATED
First Submit Date:
2019-04-09
First Submit QC Date:
None
Study First Post Date:
2019-04-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-02
Last Update Post Date:
2025-07-03
Last Update Post Date Type:
ACTUAL